Strata Skin Sciences Inc Stock News

HORSHAM, Pa., March 07, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for

Invitae (NVTA) delivered earnings and revenue surprises of -9.46% and 1.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of -10% and 11.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

HORSHAM, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for

HORSHAM, Pa., Feb. 09, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH) announced an upward revision

STRATA Skin Sciences (SSKN) entered an agreement with JuvenIL, the dermatology and aesthetics portion of Trimaco, to supply STRATA’s XTRAC excimer lasers in Israel

Enables STRATA to Commercialize and Market its XTRAC Excimer Lasers to an Estimated 300,000 Psoriasis and 160,000 Vitiligo Patients in Israel Enables STRATA to Commercialize and Market its XTRAC Excim

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo Combo In Solid Tumors BioA

STRATA Skin Sciences Inc (NASDAQ: SSKN ) expects Q4 FY21 sales of $8.8 million - $9.2 million , compared to $6.7 million in Q4 FY20 and the consensus of $8.19 million. For FY21, it expects sales of $29.7 million - $30.1 million (compared to a consensus of $29.11 million), up from $23.1 million in FY20. Cash and cash equivalents, including Full story available on Benzinga.com

STRATA Skin Sciences Inc (NASDAQ: SSKN) expects Q4 FY21 sales of $8.8 million - $9.2 million, compared to $6.7 million in Q4 FY20 and the consensus of $8.19 million. For FY21, it expects sales of $2

HORSHAM, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for

HORSHAM, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for

HORSHAM, Pa., Dec. 27, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for

HORSHAM, Pa., Dec. 27, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for t